A novel platform for cancer therapy using extracellular vesicles

Advanced Drug Delivery Reviews

Volumn 95, Issue , 2015, Pages 50-55

  Tominaga, Naoomi ^a,b,c   Yoshioka, Yusuke ^a   Ochiya, Takahiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

Author keywords

Biodistribution; Cancer; Cell cell communication; Drug delivery system; Exosome; Extracellular vesicles; MicroRNA

Indexed keywords

CELL SIGNALING; CELLS; CONTROLLED DRUG DELIVERY; DISEASES; RNA; TARGETED DRUG DELIVERY;

BIODISTRIBUTIONS; CANCER; CELL-CELL COMMUNICATIONS; DRUG DELIVERY SYSTEM; EXOSOME; EXTRACELLULAR; MICRORNAS;

CYTOLOGY;

ACID PHOSPHATASE PROSTATE ISOENZYME; CISPLATIN; CURCUMIN; DOXORUBICIN; MICRORNA; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT;

ARTICLE; BREAST TUMOR; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER THERAPY; CELL HOMING; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; ENCAPSULATION; EXOSOME; EXPRESSION VECTOR; HUMAN; MESENCHYMAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TISSUE DISTRIBUTION; TROPISM; ULTRACENTRIFUGATION; ANIMAL; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; EXTRACELLULAR VESICLES; HUMANS; NEOPLASMS; TISSUE DISTRIBUTION;

EID: 84955203483     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.10.002     Document Type: Review

References (66)

1. Brannon-Peppas L., Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 2012, 64:206-212.
2. Veronese F.M., Pasut G. PEGylation, successful approach to drug delivery REVIEWS. Drug Discov. Today 2005, 10:1451-1458.
3. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:16-20.
4. Cho K., Wang X., Nie S., Chen Z., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 2008, 14:1310-1316.
5. Al-Jamal W.T., Kostarelos K. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc. Chem. Res. 2011, 44:1094-1104.
6. Pap E., Pállinger É., Pásztói M., Falus A. Highlights of a new type of intercellular communication: microvesicle-based information transfer. Inflamm. Res. 2009, 58:1-8.
7. Kooijmans S.AA, Vader P., van Dommelen S.M., van Solinge W.W., Schiffelers R.M. Exosome mimetics: a novel class of drug delivery systems. Int. J. Nanomedicine 2012, 7:1525-1541.
8. EL Andaloussi S., Mäger I., Breakefield X.O., Wood M.J. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 2013, 12:347-357.
9. Tominaga N., Katsuda T., Ochiya T. Micromanaging of tumor metastasis by extracellular vesicles. Semin. Cell Dev. Biol. 2015, 40:52-59.
10. Raposo G., Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell Biol. 2013, 200:373-383.
11. Akers J.C., Gonda D., Kim R., Carter B.S., Chen C.C. Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J. Neurooncol. 2013, 113:1-11.
12. Gould S.J., Raposo G. As we wait: coping with an imperfect nomenclature for extracellular vesicles. J. Extracell. Vesicles 2013, 2:3-5.
13. Akao Y., Iio A., Itoh T., Noguchi S., Itoh Y., Ohtsuki Y., Naoe T. Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. Mol. Ther. 2011, 19:395-399.
14. Pan S., Yang X., Jia Y., Li R., Zhao R. Microvesicle-shuttled miR-130b reduces fat deposition in recipient primary cultured porcine adipocytes by inhibiting PPAR-?? expression. J. Cell. Physiol. 2014, 229:631-639. 10.1002/jcp.24486.
15. Lattanzi L., Federico M. A strategy of antigen incorporation into exosomes: comparing cross-presentation levels of antigens delivered by engineered exosomes and by lentiviral virus-like particles. Vaccine 2012, 30:7229-7237.
16. Yang T., Martin P., Fogarty B., Brown A., Schurman K., Phipps R., Yin V.P., Lockman P., Bai S. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio Rerio. Pharm. Res. 2015, 32:2003-2014.
17. Jang S.C., Kim O.Y., Yoon C.M., Choi D.S., Roh T.Y., Park J., Nilsson J., Lötvall J., Kim Y.K., Gho Y.S. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano 2013, 7:7698-7710.
18. Zhuang X., Xiang X., Grizzle W., Sun D., Zhang S., Axtell R.C., Ju S., Mu J., Zhang L., Steinman L., Miller D., Zhang H.G. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol. Ther. 2011, 19:1769-1779.
19. Sun D., Zhuang X., Xiang X., Liu Y., Zhang S., Liu C., Barnes S., Grizzle W., Miller D., Zhang H.G. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol. Ther. 2010, 18:1606-1614.
20. Kalani A., Kamat P.K., Chaturvedi P., Tyagi S.C., Tyagi N. Curcumin-primed exosomes mitigate endothelial cell dysfunction during hyperhomocysteinemia. Life Sci. 2014, 107:1-7.
21. Haney M.J., Klyachko N.L., Zhao Y., Gupta R., Plotnikova E.G., He Z., Patel T., Piroyan A., Sokolsky M., Kabanov A.V., Batrakova E.V. Exosomes as drug delivery vehicles for Parkinson's disease therapy. J. Control. Release 2015, 207:18-30.
22. Tian Y., Li S., Song J., Ji T., Zhu M., Anderson G.J., Wei J., Nie G. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 2014, 35:2383-2390.
23. Alvarez-Erviti L., Seow Y., Yin H., Betts C., Lakhal S., Wood M.J. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 2011, 29:341-345.
24. Federici C., Petrucci F., Caimi S., Cesolini A., Logozzi M., Borghi M., D'Ilio S., Lugini L., Violante N., Azzarito T., Majorani C., Brambilla D., Fais S. Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS One 2014, 9.
25. Pascucci L., Coccè V., Bonomi A., Ami D., Ceccarelli P., Ciusani E., Viganò L., Locatelli A., Sisto F., Doglia S.M., Parati E., Bernardo M.E., Muraca M., Alessandri G., Bondiolotti G., Pessina A. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J. Control. Release 2014, 192:262-270.
26. El-Andaloussi S., Lee Y., Lakhal-Littleton S., Li J., Seow Y., Gardiner C., Alvarez-Erviti L., Sargent I.L., Wood M.L.A. Exosome-mediated delivery of siRNA in vitro and in vivo. Nat. Protoc. 2012, 7:2112-2126.
27. Grapp M., Wrede A., Schweizer M., Hüwel S., Galla H.J., Snaidero N., Simons M., Bückers J., Low P.S., Urlaub H., Gärtner J., Steinfeld R. Choroid plexus transcytosis and exosome shuttling deliver folate into brain parenchyma. Nat. Commun. 2013, 4:2123.
28. Zhao Y., Haney M.J., Gupta R., Bohnsack J.P., He Z., Kabanov A.V., Batrakova E.V. GDNF-transfected macrophages produce potent neuroprotective effects in Parkinson's disease mouse model. PLoS One 2014, 9.
29. Rana S., Yue S., Stadel D., Zöller M. Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection. Int. J. Biochem. Cell Biol. 2012, 44:1574-1584.
30. Rana S., Claas C., Kretz C.C., Nazarenko I., Zöller M. Activation-induced internalization differs for the tetraspanins CD9 and Tspan8: impact on tumor cell motility. Int. J. Biochem. Cell Biol. 2011, 43:106-119.
31. Rountree R.B., Mandl S.J., Nachtwey J.M., Dalpozzo K., Do L., Lombardo J.R., Schoonmaker P.L., Brinkmann K., Dirmeier U., Laus R., Delcayre A. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Cancer Res. 2011, 71:5235-5244.
32. Ohno S., Takanashi M., Sudo K., Ueda S., Ishikawa A., Matsuyama N., Fujita K., Mizutani T., Ohgi T., Ochiya T., Gotoh N., Kuroda M. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 2012, 21:185-191.
33. Takahashi Y., Nishikawa M., Shinotsuka H., Matsui Y., Ohara S., Imai T., Takakura Y. Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection. J. Biotechnol. 2013, 165:77-84.
34. Kosaka N., Iguchi H., Hagiwara K., Yoshioka Y., Takeshita F., Ochiya T. Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic micrornas regulate cancer cell metastasis. J. Biol. Chem. 2013, 288:10849-10859.
35. Irina Nazarenko P.A., Rupp A.-K. Exosomes as a potential tool for a specific delivery of functional molecules. Methods Mol. Biol. 2013, 1049:495-511.
36. Aliotta J.M., Pereira M., Johnson K.W., De Paz N., Dooner M.S., Puente N., Ayala C., Brilliant K., Berz D., Lee D., Mcmillan P.N., Hixson D.C., Josic D., Quesenberry P.J. Microvesicle entry into marrow cells mediates tissue-specific changes in mRNA by direct delivery of mRNA and induction of transcription. Cell 2011, 38:233-245.
37. Koga K., Matsumoto K., Akiyoshi T., Kubo M., Yamanaka N., Tasaki A., Nakashima H., Nakamura M., Kuroki S., Tanaka M., Katano M. Purification, characterization and biological significance of tumor-derived exosomes. Anticancer Res. 2005, 25:3703-3707.
38. Nordin J.Z., Lee Y., Vader P., Mäger I., Johansson H.J., Heusermann W., Wiklander O.P.B., Hällbrink M., Seow Y., Bultema J.J., Gilthorpe J., Davies T., Fairchild P.J., Gabrielsson S., Meisner-Kober N.C., Lehtiö J., Smith C.I.E., Wood M.J.A., Andaloussi S.E.L. Ultrafiltration with size-exclusion liquid chromatography for high yield isolation of extracellular vesicles preserving intact biophysical and functional properties. Nanomed. Nanotechnol. Biol. Med. 2015, 11:879-883.
39. Rupert D.L.M., Lässer C., Eldh M., Block S., Zhdanov V.P., Lotvall J., Bally M., Höök F. Determination of exosome concentration in solution using surface plasmon resonance spectroscopy. Anal. Chem. 2014, 86:5929-5936.
40. Maas S.L.N., de Vrij J., van der Vlist E.J., Geragousian B., van Bloois L., Mastrobattista E., Schiffelers R.M., Wauben M.H.M., Broekman M.L.D., Nolte-'t Hoen E.N.M. Possibilities and limitations of current technologies for quantification of biological extracellular vesicles and synthetic mimics. J. Control. Release 2015, 200:87-96.
41. Zhou H., Yuen P.S.T., Pisitkun T., Gonzales P.A., Yasuda H., Dear J.W., Gross P., Knepper M.A., Star R.A. Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery. Kidney Int. 2006, 69:1471-1476.
42. Munoz J.L., Bliss S.A., Greco S.J., Ramkissoon S.H., Ligon K.L., Rameshwar P. Delivery of functional Anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol. Ther. Nucleic Acids 2013, 2:e126.
43. Raposo G., Nijman H.W., Stoorvogel W., Liejendekker R., Harding C.V., Melief C.J., Geuze H.J. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 1996, 183:1161-1172.
44. Zitvogel L., Regnault A., Lozier A., Wolfers J., Flament C., Tenza D., Ricciardi-Castagnoli P., Raposo G., Amigorena S. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med. 1998, 4:594-600.
45. Wolfers J., Lozier A., Raposo G., Regnault A., Théry C., Masurier C., Flament C., Pouzieux S., Faure F., Tursz T., Angevin E., Amigorena S., Zitvogel L. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 2001, 7:297-303.
46. Nanjundappa R.H., Wang R., Xie Y., Umeshappa C.S., Chibbar R., Wei Y., Liu Q., Xiang J. GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4+ T-independent CTL responses. Vaccine 2011, 29:3538-3547.
47. Zech D., Rana S., Büchler M.W., Zöller M. Tumor-exosomes and leukocyte activation: an ambivalent crosstalk. Cell Commun. Signal. 2012, 10:37.
48. Hao S., Yuan J., Xiang J. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory. J. Leukoc. Biol. 2007, 82:829-838.
49. Hao S., Liu Y., Yuan J., Zhang X., He T., Wu X., Wei Y., Sun D., Xiang J. Novel exosome-targeted CD4+ T cell vaccine counteracting CD4+25+ regulatory T cell-mediated immune suppression and stimulating efficient central memory CD8+ CTL responses. J. Immunol. 2007, 179:2731-2740.
50. Shen C., Hao S.G., Zhao C.X., Zhu J., Wang C. Antileukaemia immunity: effect of exosomes against NB4 acute promyelocytic leukaemia cells. J. Int. Med. Res. 2011, 39:740-747.
51. Natasha G., Gundogan B., Tan A., Farhatnia Y., Wu W., Rajadas J., Seifalian A.M. Exosomes as immunotheranostic nanoparticles. Clin. Ther. 2014, 36:820-829.
52. Morse M.A., Garst J., Osada T., Khan S., Hobeika A., Clay T.M., Valente N., Shreeniwas R., Sutton M.A., Delcayre A., Hsu D., Le Pecq J., Lyerly H.K. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J. Transl. Med. 2005, 3:9.
53. Escudier B., Dorval T., Chaput N., André F., Caby M.-P., Novault S., Flament C., Leboulaire C., Borg C., Amigorena S., Boccaccio C., Bonnerot C., Dhellin O., Movassagh M., Piperno S., Robert C., Serra V., Valente N., Le Pecq J., Spatz A., Lantz O., Tursz T., Angevin E., Zitvogel L. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J. Transl. Med. 2005, 3:10.
54. Dai S., Wei D., Wu Z., Zhou X., Wei X., Huang H., Li G. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol. Ther. 2008, 16:782-790.
55. Van Dommelen S.M., Vader P., Lakhal S., Kooijmans S.A.A., Van Solinge W.W., Wood M.J.A., Schiffelers R.M. Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. J. Control. Release 2012, 161:635-644.
56. Smyth T., Kullberg M., Malik N., Smith-Jones P., Graner M.W., Anchordoquy T.J. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. J. Control. Release 2015, 199:145-155.
57. Lai C.P., Mardini O., Ericsson M., Prabhakar S., Maguire C.A., Chen J.W., Tannous B.A., Breakefield X.O. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. ACS Nano 2014, 8:483-494.
58. Wiklander O.P.B., Nordin J.Z., O'Loughlin A., Gustafsson Y., Corso G., Mäger I., Vader P., Lee Y., Sork H., Seow Y., Heldring H., Alvarez-Erviti L., Smith C.E., Le Blanc K., Macchiarini P., Jungebluth P., Wood M.J.A., Andaloussi A.E. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J. Extracell. Vesicles 2015, 4:26316.
59. Grange C., Tapparo M., Bruno S., Chatterjee D., Quesenberry P.J., Tetta C., Camussi G. Biodistribution of mesenchymal stem cell-derived extracellular vesicles in a model of acute kidney injury monitored by optical imaging. Int. J. Mol. Med. 2014, 33:1055-1063.
60. Inder K.L., Ruelcke J.E., Petelin L., Moon H., Choi E., Rae J., Blumenthal A., Hutmacher D., Saunders N.A., Stow J.L., Parton R.G., Hill M.M. Cavin-1/PTRF alters prostate cancer cell-derived extracellular vesicle content and internalization to attenuate extracellular vesicle-mediated osteoclastogenesis and osteoblast proliferation. J. Extracell. Vesicles 2014, 3:1-14.
61. Peinado H., Alečković M., Lavotshkin S., Matei I., Costa-Silva B., Moreno-Bueno G., Hergueta-Redondo M., Williams C., García-Santos G., Ghajar C.M., Nitadori-Hoshino A., Hoffman C., Badal K., Garcia B.A., Callahan M.K., Yuan J., Martins V.R., Skog J., Kaplan R.N., Brady M.S., Wolchok J.D., Chapman P.B., Kang Y., Bromberg J., Lyden D. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012, 18:883-891.
62. Fong M.Y., Zhou W., Liu L., Alontaga A.Y., Chandra M., Ashby J., Chow A., O'Connor S.T.F., Li S., Chin A.R., Somlo G., Palomares M., Li Z., Tremblay J.R., Tsuyada A., Sun G., Reid M.A., Wu X., Swiderski P., Ren X., Shi Y., Kong M., Zhong W., Chen Y., Wang S.E. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat. Cell Biol. 2015, 17:183-194.
63. Tominaga N., Kosaka N., Ono M., Katsuda T., Yoshioka Y., Tamura K., Lötvall J., Nakagama H., Ochiya T. Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat. Commun. 2015, 6:6716.
64. Chow A., Zhou W., Liu L., Fong M.Y., Champer J., Van Haute D., Chin A.R., Ren X., Gugiu B.G., Meng Z., Huang W., Ngo V., Kortylewski M., Wang S.E. Macrophage immunomodulation by breast cancer-derived exosomes requires Toll-like receptor 2-mediated activation of NF-κB. Sci. Rep. 2014, 4:5750.
65. Hood J.L., San Roman S., Wickline S.A. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 2011, 71:3792-3801.
66. Zomer A., Maynard C., Verweij F.J., Kamermans A., Schäfer R., Beerling E., Schiffelers R.M., Wit E.D., Berenguer J., Ellenbroek S.I.J., Wurdinger T., Pegtel D.M., Rheenen J.V. In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell 2015, 161:1046-1057.